Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more
Molecular Partners AG - Asset Resilience Ratio
Molecular Partners AG (MLLCF) has an Asset Resilience Ratio of 19.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Molecular Partners AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Molecular Partners AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $22.16 Million | 19.76% |
| Total Liquid Assets | $22.16 Million | 19.76% |
Asset Resilience Insights
- Good Liquidity Position: Molecular Partners AG maintains a healthy 19.76% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Molecular Partners AG Industry Peers by Asset Resilience Ratio
Compare Molecular Partners AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Molecular Partners AG (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Molecular Partners AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 53.97% | $85.56 Million | $158.53 Million | -6.31pp |
| 2023-12-31 | 60.29% | $119.58 Million | $198.35 Million | -1.18pp |
| 2022-12-31 | 61.47% | $161.20 Million | $262.26 Million | +26.14pp |
| 2021-12-31 | 35.33% | $61.00 Million | $172.67 Million | +14.00pp |
| 2020-12-31 | 21.33% | $40.00 Million | $187.55 Million | +2.87pp |
| 2019-12-31 | 18.46% | $19.37 Million | $104.94 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $155.16 Million | -- |
| 2017-12-31 | 6.75% | $9.74 Million | $144.42 Million | -9.81pp |
| 2016-12-31 | 16.56% | $30.49 Million | $184.10 Million | +7.44pp |
| 2015-12-31 | 9.13% | $20.02 Million | $219.40 Million | -- |